CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.
Clinical trial NCT04639362 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04639362
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-29
- Primary completion
- 2025-12-01
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.